PharmVille
  • Home
  • Company Search
  • Search Jobs
  • Post Your Resume
  • Post A Job
  • Employers
  • Sign in
  • Sign up
  • Home
  • Company Search
  • Search Jobs
  • Post Your Resume
  • Post A Job
  • Employers

2 general business jobs found in Hazlet, NJ

Refine Search
Current Search
Marketing Hazlet, NJ general business
Search within
50 miles
10 miles 20 miles 50 miles 100 miles 200 miles
Refine by Categories
Pharmaceutical  (1437) General Business  (1419) Science  (1374) Business Development  (825) Sales  (825) Biotech  (808)
Entry Level  (15) Customer Service  (3) Health Care  (3) Consultant  (2) Manufacturing  (2) Quality Control  (2)
More
Refine by City
Bridgewater  (1) New York  (1)
Vertex
Dec 11, 2025
Heme Territory Manager - Metro Northeast
Vertex New York, NY, USA
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has three approved medicines that treat the underlying cause of cystic fibrosis (CF) – a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney disease.
Amarin
Nov 24, 2025
Director of Trade
Amarin Bridgewater, NJ, USA
Amarin Corporation plc (“Amarin”) is a rapidly growing pharmaceutical company developing and selling therapeutics to improve cardiovascular health. Amarin, a publicly traded company (NASDAQ: AMRN) with approximately 900 employees, is headquartered in Dublin, Ireland and has its US operations (Amarin Pharma Inc.) based in Central New Jersey. Amarin has successfully developed, registered and launched VASCEPA® in the U.S. market with a network of third-party companies aligned with Amarin to advance commercialization of VASCEPA® globally. In the U.S., VASCEPA® was launched in 2013 for its initial indication of as a treatment of Very High Triglycerides (i.e. patients with TG levels ≥ 500mg/dL). In November 2018, unprecedented clinical results were announced from a landmark global cardiovascular outcomes study in which VASCEPA®demonstrated a significantly lower risk of cardiovascular events beyond the current standard of care for cholesterol management....
  • Home
  • Contact
  • About Us
  • Terms & Conditions
  • Employer
  • Post a Job
  • Search Resumes
  • Sign in
  • Job Seeker
  • Find Jobs
  • Resume Services
  • Post Your Resume
  • Facebook
  • LinkedIN
  • Twitter
© 2008-2025 Powered by PharmVille